CD6F-engineered CAR T cells

CD6F-engineered CAR T cells are an investigational adoptive cell therapy platform where Chimeric Antigen Receptor (CAR) T cells are modified to overexpress the CD6F splice isoform of the CD6 adhesion molecule. CD6 is a surface glycoprotein that regulates T-cell activation and survival; the CD6F isoform, which lacks exon 9, is engineered to decouple tonic signaling from antigen-induced activation. This modification enhances the metabolic plasticity of the T cells by improving both glycolytic and oxidative phosphorylation (OXPHOS) capacities, leading to increased functional durability and resistance to exhaustion. Preclinical studies, particularly in HER2-positive glioblastoma and CD19-positive models, have demonstrated that CD6F-engineered CAR T cells exhibit superior persistence and antitumor control compared to conventional CAR T cell designs.

Other names

CD6F-expressing CAR T cellsCD-6F-expressing CAR T cellsCD 6F-expressing CAR T cellsCD6F-modified CAR T cellsCD-6F-modified CAR T cellsCD 6F-modified CAR T cells